Get started
Author

Andrew Blauvelt

Human Langerhans Cells Express E-Cadherin
1995 · Andrew Blauvelt, Stephen I. Katz, et al. · Journal of Investigative Dermatology · 83
Human Herpesvirus 8 Infection Occurs following Adolescence in the United States
1997 · Andrew Blauvelt, Shizuko Sei, et al. · The Journal of Infectious Diseases · 76
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
2023 · Andrew Blauvelt, Barry Ladizinski, et al. · Journal of the American Academy of Dermatology · 54
PDF
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
2024 · Andrew Blauvelt, Zoe D. Draelos, et al. · Journal of the American Academy of Dermatology · 48
PDF
Long-term radiographic follow-up after isotretinoin therapy
1988 · Charles N. Ellis, David R. Pennes, et al. · Journal of the American Academy of Dermatology · 40
The Skin as Target, Vector, and Effector Organ in Human Immunodeficiency Virus Disease
1995 · Andrew Blauvelt, Stephen I. Katz · Journal of Investigative Dermatology · 23
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials
2023 · Andrew Blauvelt, Mark Lebwohl, et al. · Journal of the American Academy of Dermatology · 22
PDF
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis
2023 · Andrew Blauvelt, Phoebe Rich, et al. · Journal of the American Academy of Dermatology · 21
PDF
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors
2025 · Andrew Blauvelt, Bruce E. Strober, et al. · Journal of the American Academy of Dermatology · 19
Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study
2023 · Karen A. Veverka, Steven T.G. Thng, et al. · Journal of the American Academy of Dermatology · 19
Content evaluation of pruritus, skin pain and sleep disturbance patient-reported outcome measures for adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviews
2024 · Andrew Blauvelt, Jennifer Reckleff, et al. · British Journal of Dermatology · 13
Metastases from basal cell carcinoma of the scrotum
1992 · George T. Nahass, Andrew Blauvelt, et al. · Journal of the American Academy of Dermatology · 13
Defining On-Treatment Remission in Plaque Psoriasis
2025 · April W. Armstrong, George C. Gondo, et al. · JAMA Dermatology · 12
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks
2025 · Alan D. Irvine, Vimal H. Prajapati, et al. · American Journal of Clinical Dermatology · 11
PDF
Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study
2025 · Andrew Blauvelt, Petr Arenberger, et al. · Journal of the American Academy of Dermatology · 10
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study
2025 · Kim A. Papp, Shahram Jacobs, et al. · Journal of the American Academy of Dermatology · 7
Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study
2026 · Jonathan I. Silverberg, Lindsay Ackerman, et al. · Dermatology and Therapy · 6
PDF
Comparing how Well Abrocitinib and Dupilumab Treat Atopic Dermatitis Signs and Symptoms: A Plain Language Summary
2023 · Kristian Reich, Jacob P. Thyssen, et al. · Immunotherapy · 6
Ixekizumab and Malignant Neoplasms
2025 · Joseph F. Merola, Kim A. Papp, et al. · JAMA Dermatology · 5
Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
2024 · Mark Lebwohl, Bruce Strober, et al. · Drugs - Real World Outcomes · 5
Oral delivery of an ustekinumab biosimilar with bioavailability comparable to subcutaneous administration in healthy human participants
2026 · Joshua T. Myers, Alyson Yamaguchi, et al. · European Journal of Clinical Pharmacology · 2
PDF
Psychometric Evaluation of Skin Pain and Sleep Disturbance Numeric Rating Scales in Moderate-to-Severe Atopic Dermatitis
2026 · Andrew Blauvelt, Kimberly M. Deininger, et al. · Dermatology and Therapy · 1
PDF
158 APG777, a Novel, Half-Life Extended Anti-IL-13 Antibody, Demonstrates Safety and Efficacy in Moderate-to-Severe Atopic Dermatitis: 16-Week Results From the Phase 2 APEX Study
2025 · Emma Guttman-Yassky, Andrew Blauvelt, et al. · Journal of Investigative Dermatology · 1
Psychometric Evaluation of Worst Pruritus Numeric Rating Scale in Adults With Moderate-to-Severe Atopic Dermatitis
2026 · Andrew Blauvelt, Angela Williams, et al. · Dermatology and Therapy
PDF
Durable maintenance of EASI-90 with amlitelimab in adults with moderate-to-severe atopic dermatitis: 52-week results from the STREAM-AD phase 2b trial
2025 · Andrew Blauvelt, Bruce Strober, et al. · SKIN The Journal of Cutaneous Medicine
PDF
Works count: 40
Citation count: 496
H-index: 12
I10-index: 15
Year
Topic
Type